NASDAQ$OSUR

OraSure Technologies Inc · Q2 2021 earnings

Q2 2021 earnings · · Investor relations

Briefing

OraSure's Q2 2021 performance was marked by a strong rebound in the core business, driven by a 97% increase in revenue compared to the previous year. The company received three Emergency Use Authorizations (EUAs) for its InteliSwab™ COVID-19 Rapid Tests and experienced significant growth in its Molecular Solutions business unit.

OraSure Technologies reported a strong second quarter in 2021, with net revenues of $57.6 million, a 97% increase from Q2 2020. The company's core business rebounded to pre-pandemic levels, and it received three EUAs for its InteliSwab™ COVID-19 Rapid Tests. The Molecular Solutions business unit saw significant growth, driven by demand for genomic collection kits and microbiome services.

  • Net revenues for Q2 2021 were $57.6 million, a 97% increase year-over-year.
  • Excluding COVID-19 product revenues, revenues for the quarter increased 122% YoY.
  • The company received three Emergency Use Authorizations (EUAs) for its InteliSwab™ COVID-19 Rapid Tests.
  • Operating income in the second quarter was $1.8 million, compared to a loss of ($9.4) million in the second quarter of last year.

Headline financials

Total Revenue

$57.6M

Previous: $29.3M+96.9%
EPS (adj)

-$0.02

Previous: -$0.16+87.5%
Capital Expenditures

-$11.9M

Previous: -$3.44M-244.8%
Free Cash Flow

-$13.2M

Previous: -$13.9M+5.1%
Net Income

-$1.36M

Previous: -$10.5M+87.0%
Operating Income

$1.8M

Previous: -$9.4M+119.1%
Gross Profit

$30.7M

Previous: $17.3M+77.7%
Cash & Equivalents

$158M

Previous: $174M-9.1%
Total Assets

$465M

Previous: $421M+10.5%
Stock-Based Comp

$1.47M

Previous: $2.67M-44.9%

Revenue & EPS history

OraSure · Revenue · Quarterly

$57.6M

Q2 2021+96.9%vs Q2 2020
Beat estimate in 13 of 16 quarters(81%)
ActualEstimate

Forward guidance

The Company expects third quarter 2021 net revenues to range from $45 million to $50 million. The Company has also provided guidance for InteliSwab™ for the full year stating that in now anticipates total InteliSwab™ sales through December 2021 of approximately $30 million with the preponderance of revenue coming in the fourth quarter of calendar year 2021. The Company expects fiscal year 2021 total revenue of approximately $230 million.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q2 2021

Historical avgQ2 2021

-2.1%

Avg return

Earnings day

+0.4%

Avg return

5 days after

-2.4%

Avg return

30 days after

39%

25 / 64 earnings

Positive

+31.7%

Q2 2023

Best reaction

-32.1%

Q2 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-2.2%-2.9%
Q4 2025+10.0%+6.4%+7.1%
Q3 2025-6.6%-4.3%-3.1%
Q1 2025-6.8%-5.0%+3.6%
Q4 2024-23.5%-10.8%-14.2%
Q3 2024-1.2%-1.2%-8.9%
Q2 2024+2.6%-0.2%+5.7%
Q1 2024-8.8%-6.9%-15.3%
Q4 2023+10.3%+3.7%-12.3%
Q3 2023+4.9%+14.5%+22.2%
Q2 2023+31.7%+43.9%+42.8%
Q1 2023+9.2%-20.8%-22.3%
Q4 2022+10.4%+18.8%+30.1%
Q3 2022+0.7%+20.8%+18.5%
Q2 2022+28.3%+38.6%+18.8%
Q1 2022-8.9%-3.9%-48.8%
Q4 2021-1.3%-0.8%-13.0%
Q3 2021-4.9%-7.7%-19.8%
Q2 2021+1.2%-0.7%-4.1%
Q1 2021+5.0%+5.1%+0.2%
Q4 2020-2.3%+2.1%+1.5%
Q3 2020-15.6%-15.4%-20.6%
Q2 2020-32.1%-24.6%-46.9%
Q1 2020+6.1%+15.6%-33.1%
Q4 2019-6.7%-6.1%+8.5%
Q3 2019-3.1%-6.9%-10.3%
Q2 2019-3.3%-5.2%-14.4%
Q1 2019-8.0%-12.6%-12.7%
Q4 2018-25.5%-18.3%-14.8%
Q3 2018-8.7%-6.6%-15.0%
Q2 2018-0.6%-1.0%-5.8%
Q1 2018-15.4%-11.0%-2.4%
Q4 2017-12.8%-13.4%-9.5%
Q3 2017-30.3%-26.6%-13.8%
Q2 2017+13.5%+19.4%+17.4%
Q1 2017+16.9%+10.9%+17.6%
Q4 2016+18.9%+18.9%+29.9%
Q3 2016-0.1%+1.4%+14.3%
Q2 2016+4.6%+8.5%+30.7%
Q1 2016-6.6%
Q4 2015+14.7%
Q3 2015+0.4%
Q2 2015+7.0%
Q1 2015-12.3%
Q4 2014-11.9%
Q3 2014+2.9%
Q2 2014-7.7%
Q1 2014-9.2%
Q4 2013+9.5%
Q3 2013-0.3%
Q2 2013+10.2%
Q1 2013-0.4%
Q4 2012-12.4%
Q3 2012-16.4%
Q2 2012-7.1%
Q1 2011+5.0%
Q1 2012-5.9%
Q4 2011+4.6%
Q3 2011-5.6%
Q4 2010-12.5%
Q2 2011-12.5%
Q3 2010+6.6%
Q2 2010-7.0%
Q1 2010-15.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro